167 related articles for article (PubMed ID: 9623955)
1. Tamoxifen, raloxifene findings unlikely to encourage genetic screening for breast cancer.
Dove A
Nat Med; 1998 Jun; 4(6):647. PubMed ID: 9623955
[No Abstract] [Full Text] [Related]
2. Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow.
Jordan VC
J Natl Cancer Inst; 1998 Jul; 90(13):967-71. PubMed ID: 9665143
[No Abstract] [Full Text] [Related]
3. Should you be taking tamoxifen?
Johns Hopkins Med Lett Health After 50; 2001 Jun; 13(4):4-5. PubMed ID: 11439691
[No Abstract] [Full Text] [Related]
4. Breast cancer genetics. Implications of clinical practice.
Olufunmilayo I; Olopade MD; Fackenthal JD
Hematol Oncol Clin North Am; 2000 Jun; 14(3):705-25. PubMed ID: 11203330
[No Abstract] [Full Text] [Related]
5. Molecular biology of the estrogen receptor aids in the understanding of tamoxifen resistance and breast cancer prevention with raloxifene.
Jordan VC
Recent Results Cancer Res; 1998; 152():265-76. PubMed ID: 9928564
[No Abstract] [Full Text] [Related]
6. New hope for prevention, treatment of breast cancer.
Harv Health Lett; 1998 Aug; 23(10):6-7. PubMed ID: 9723013
[No Abstract] [Full Text] [Related]
7. Of designer drugs, magic bullets, and gold standards.
Rifkind BM; Rossouw JE
JAMA; 1998 May; 279(18):1483-5. PubMed ID: 9600485
[No Abstract] [Full Text] [Related]
8. Anti-estrogens come of age: a pioneer looks back.
Nelson NJ
J Natl Cancer Inst; 1998 May; 90(9):646-7. PubMed ID: 9586657
[No Abstract] [Full Text] [Related]
9. Tamoxifen for prevention of breast cancer.
Med Lett Drugs Ther; 1999 Jan; 41(1043):1-2. PubMed ID: 9924486
[No Abstract] [Full Text] [Related]
10. Encouraging news from the SERM frontier. Selective estrogen receptor modulator.
Franks AL; Steinberg KK
JAMA; 1999 Jun; 281(23):2243-4. PubMed ID: 10376579
[No Abstract] [Full Text] [Related]
11. Status of antiestrogen breast cancer prevention trials.
Powles TJ
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):28-31. PubMed ID: 9556788
[TBL] [Abstract][Full Text] [Related]
12. Designer estrogens.
Jordan VC
Sci Am; 1998 Oct; 279(4):60-7. PubMed ID: 9768522
[No Abstract] [Full Text] [Related]
13. Until there's more information, caution advised in using tamoxifen or raloxifene for breast cancer prevention.
Mayo Clin Health Lett; 1998 Jul; 16(7):4. PubMed ID: 9663019
[No Abstract] [Full Text] [Related]
14. Estrogen receptor as a target for the prevention of breast cancer.
Jordan VC
J Lab Clin Med; 1999 May; 133(5):408-14. PubMed ID: 10235123
[No Abstract] [Full Text] [Related]
15. Tamoxifen, raloxifene, and the prevention of breast cancer.
Jordan VC; Morrow M
Endocr Rev; 1999 Jun; 20(3):253-78. PubMed ID: 10368771
[No Abstract] [Full Text] [Related]
16. A 40-year-old woman with a strong family history of breast cancer.
Garber J
JAMA; 1999 Nov; 282(20):1953-60. PubMed ID: 10580462
[No Abstract] [Full Text] [Related]
17. Gonadal hormone substitutes: effects on the cardiovascular system.
Clarkson TB; Cline JM; Williams JK; Anthony MS
Osteoporos Int; 1997; 7 Suppl 1():S43-51. PubMed ID: 9205646
[No Abstract] [Full Text] [Related]
18. Application of breast cancer risk prediction models in clinical practice.
Domchek SM; Eisen A; Calzone K; Stopfer J; Blackwood A; Weber BL
J Clin Oncol; 2003 Feb; 21(4):593-601. PubMed ID: 12586794
[TBL] [Abstract][Full Text] [Related]
19. Development of a new prevention maintenance therapy for postmenopausal women.
Jordan VC
Recent Results Cancer Res; 1999; 151():96-109. PubMed ID: 10337721
[TBL] [Abstract][Full Text] [Related]
20. The prevention pill.
Gibbs WW
Sci Am; 1998 Jun; 278(6):26-7. PubMed ID: 9644010
[No Abstract] [Full Text] [Related]
[Next] [New Search]
